Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)
Work
Year: 2023
Type: article
Source: Blood
Authors Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann +23 more
Institutions The University of Texas MD Anderson Cancer Center, Mayo Clinic in Arizona, Washington University in St. Louis, University of Iowa, Emory University +6 more
Cites:
Cited by: 4
Related to: 10
FWCI: 1.816
Citation percentile (by year/subfield): 56.79
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze